First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

NCT06603844 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: CRB-601 monoclonal antibody
DRUG: Anti-PD-1 monoclonal antibody

Sponsor

Corbus Pharmaceuticals Inc.